On December 18, 2019 Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a leader in digital therapeutics, reported a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes (Press release, Voluntis, DEC 18, 2019, View Source [SID1234552531]). This collaboration will leverage Voluntis’ Theraxium Oncology, the company’s core platform for digital therapeutics in the field of oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to enabling self-management of symptoms, data analytics and automated triage capabilities will make it possible for integrated care teams to monitor patients remotely and engage directly with them at the appropriate time. The digital therapeutic will be evaluated in an upcoming prospective clinical trial. The new collaboration uses Voluntis’ multi-disciplinary expertise in implementing digital therapeutics intended to support real-world use of a cancer therapy.

"We are delighted to work with Novartis, a leader in cancer therapies, to empower patients and care teams to manage their breast cancer treatment journey with best-in-class digital innovation," said Pierre Leurent, CEO, Voluntis. "This new collaboration also reinforces Theraxium Oncology as the backbone for digital therapeutics that support patients and their care teams across the spectrum of cancer care."